Alnylam Pharmaceuticals (DE:DUL)
FRANKFURT:DUL
Holding DE:DUL?
Track your performance easily

Alnylam Pharma (DUL) Financial Statements

1 Followers

Alnylam Pharma Financial Overview

Alnylam Pharma's market cap is currently ―. The company's EPS TTM is €; its P/E ratio is ―; Alnylam Pharma is scheduled to report earnings on February 6, 2025, and the estimated EPS forecast is €-0.55. See an overview of income statement, balance sheet, and cash flow financials.
Sep 24Jun 24Mar 24Dec 23Sep 23
Income Statement-
Total Revenue$ 500.92M$ 659.83M$ 494.33M$ 439.72M$ 750.53M
Gross Profit$ 418.94M$ 592.55M$ 439.72M$ 340.42M$ 671.06M
EBIT$ -108.66M$ -11.17M$ -16.97M$ -106.35M$ 150.74M
EBITDA$ -95.61M$ -1.48M$ -5.00M$ -82.38M$ 160.94M
Net Income Common Stockholders$ -111.57M$ -16.89M$ -65.94M$ -137.87M$ 147.75M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 2.78B$ 2.62B$ 2.37B$ 2.44B$ 2.41B
Total Assets$ 4.21B$ 4.01B$ 3.82B$ 3.83B$ 3.84B
Total Debt$ 1.30B$ 1.30B$ 1.30B$ 1.31B$ 1.31B
Net Debt$ -1.48B$ -1.32B$ -1.07B$ -1.13B$ -1.10B
Total Liabilities$ 4.17B$ 4.01B$ 4.04B$ 4.05B$ 4.00B
Stockholders Equity$ 32.35M$ -3.07M$ -219.27M$ -220.64M$ -165.87M
Cash Flow-
Free Cash Flow$ 39.52M$ 116.14M$ -94.49M$ -45.10M$ 342.32M
Operating Cash Flow$ 43.71M$ 124.16M$ -81.52M$ -29.80M$ 359.41M
Investing Cash Flow$ -30.25M$ 33.94M$ -67.62M$ -240.66M$ -10.76M
Financing Cash Flow$ 102.75M$ 131.50M$ 28.91M$ 39.23M$ 33.14M
Currency in USD

Alnylam Pharma Earnings and Revenue History

Alnylam Pharma Debt to Assets

Alnylam Pharma Cash Flow

Alnylam Pharma Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis